Balyasny Asset Management
BLFS icon

Balyasny Asset Management’s BioLife Solutions BLFS Stock Holding History

Balyasny Asset Management’s Portfolio BLFS Stock Details BLFS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-102,250
Closed -$1.41M – 2504
2023
Q3 		$1.41M Buy
102,250
+38,559
+61% +$608K ﹤0.01% 1475
2023
Q2 		$1.41M Buy
+63,691
New +$1.34M ﹤0.01% 1497

Other funds holding BLFS

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's BLFS Position: Q4 2023 in Review

Balyasny Asset Management sold out of BioLife Solutions (BLFS) in Q4 2023, closing a stake of 102,250 shares — an estimated $1.41M sold.

Balyasny Asset Management first reported a position in BLFS in Q2 2023 and held it in 2 quarters. The position peaked at $1.41M in Q3 2023. 140 funds tracked by Wall St. Rank hold BLFS as of Q4 2023.

  • Balyasny Asset Management reported no remaining BioLife Solutions position as of Q4 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 102,250 BioLife Solutions shares in Q4 2023, an estimated $1.41M.
  • Balyasny Asset Management first reported a position in BioLife Solutions in Q2 2023 and held it in 2 quarters.
  • Balyasny Asset Management's BioLife Solutions position peaked at $1.41M in Q3 2023.
  • 140 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2023.

Based on Balyasny Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.